| | | Costs ($) | Life years | QALYs | ICERs ($/LY) | ICURs ($/QALYs) |
| | Chemo | 94,492 | 4.86 | 3.47 | — | — | |
Bosutinib → chemo/SCT | 676,243 | 9.06 | 6.86 | Weakly dominated | Weakly dominated | | Imatinib → chemo/SCT | 749,272 | 9.61 | 7.29 | 137,900 | 171,700 | | Nilotinib → chemo/SCT | 884,222 | 10.08 | 7.65 | Weakly dominated | Weakly dominated | | Dasatinib → chemo/SCT | 912,367 | 10.02 | 7.61 | Dominated | Dominated | | Bosutinib → nilotinib → chemo/SCT | 913,682 | 9.96 | 7.82 | Dominated | Weakly dominated | | Bosutinib → ponatinib → chemo/SCT | 947,136 | 9.92 | 7.80 | Dominated | Dominated | | Imatinib → nilotinib → chemo/SCT | 965,597 | 10.44 | 8.14 | 260,800 | 253,500 | | Imatinib → ponatinib → chemo/SCT | 995,868 | 10.40 | 8.12 | Dominated | Dominated | | Imatinib → bosutinib → chemo/SCT | 1,020,857 | 10.57 | 8.22 | Weakly dominated | Weakly dominated | | Bosutinib → dasatinib → chemo/SCT | 1,062,220 | 10.45 | 8.14 | Dominated | Dominated | | Imatinib → dasatinib → chemo/SCT | 1,099,065 | 10.88 | 8.43 | Weakly dominated | Weakly dominated | | Nilotinib → ponatinib → chemo/SCT | 1,108,291 | 10.80 | 8.39 | Dominated | Dominated | | Dasatinib → nilotinib → chemo/SCT | 1,111,549 | 10.79 | 8.38 | Dominated | Dominated | | Nilotinib → bosutinib → chemo/SCT | 1,130,750 | 10.95 | 8.48 | Weakly dominated | Weakly dominated | | Dasatinib → ponatinib → chemo/SCT | 1,139,314 | 10.75 | 8.35 | Dominated | Dominated | | Dasatinib → bosutinib → chemo/SCT | 1,162,092 | 10.90 | 8.45 | Dominated | Dominated | | Nilotinib → dasatinib → chemo/SCT | 1,200,921 | 11.23 | 8.67 | 299,800 | 445,100 |
|
|
